This article provides additional data on the association of the new adipokine CTRP1 with the incidence of future major adverse cardiovascular events in a prospective cohort of patients undergoing coronary angiography. In this regard, multivariable Cox proportional hazards models taking into account cardiac risk markers are presented. Additionally, data on the impact of baseline variables including metabolic traits and co-morbidities on the incidence of future major adverse cardiovascular events are shown. This data article is associated to the research article titled 'The Novel Adipokine CTRP1 is Significantly Associated with the Incidence of Major Adverse Cardiovascular Events' Muendlein et al., 2019. 
Data
A significant association between CTRP1 and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography has been reported in the associated research article [1] . In addition to the baseline characteristics of the selected study population given in the main article, Table  1 of this article shows the impact of most baseline variables on the incidence of MACE. Table 2 shows further data regarding multivariable Cox proportional hazards models adjusting for age, sex, body mass index, type 2 diabetes mellitus, significant coronary artery disease, hypertension, smoking, LDL cholesterol, HDL cholesterol, and estimated glomerular filtration rate and additionally for the extent of coronary artery disease as well as the percentage of left ventricular ejection fraction (model a) or inflammatory markers including fibrinogen and C-reactive protein (model b).
Experimental design, materials and methods
The present dataset included 539 consecutive Caucasian patients, who were referred to elective coronary angiography for the evaluation of established or suspected stable CAD at the academic teaching hospital Feldkirch, Austria. Baseline characteristics were obtained as described in the associated main article [1] and in previous reports [2, 3] . In short, the extent of atherosclerosis was defined as the number of !50% lesions. Left ventricular function was assessed by 2D echocardiography. Venous blood samples were collected after an overnight fast of 12 h prior to angiography and laboratory measurements were performed from fresh serum or plasma samples or from serum or plasma samples Specifications [1] .
Value of the data
The data presented here further characterize included patients by showing the impact of baseline variables on the incidence of major adverse cardiovascular events in patients undergoing coronary angiography, which may differ from the general population. The data presented here stressed the impact of CTRP1 on future cardiovascular risk beyond its association with traditional coronary risk factors and, therefore, may stimulate further research on the role of CTRP1 in the development of cardiovascular disease. These data are important, because the existing literature about CTRP1 is still limited, and therefore, they particularly extend the knowledge regarding the association between CTRP1 and cardiovascular disease.
stored at À80 C. C-reactive protein (CRP) was measured by particle enhanced immunological agglutination (Roche, Switzerland) on a Hitachi Cobas 501. Serum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Brno, Czech Republic; article number: RD191153100R). During a mean follow-up period of 5.9 ± 2.2 years (with a total of 8 years) cardiovascular events were recorded. Out of the 539 patients initially included in the present study, 15 subjects were lost to follow-up. MACE was defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Time and causes of death were regularly obtained from a national survey (Statistik Austria, Vienna, Austria) or from hospital records.
Hazard ratios (HRs) and 95% confidence intervals of the HRs were derived from univariable and multivariable Cox proportional hazards models; log-transformed continuous variables were z- Results of univariate Cox regression analysis. Age, BMI, LDL-C, HDL-C, triglycerides, eGFR, LVEF, C-reactive protein, fibrinogen, and BNP were log-transformed and z-transformed before analysis. Coronary artery stenoses with stenotic narrowing !50% were defined as significant CAD. The extent of CAD was defined as the number of !50% lesions. BMI, body mass index; eGFR, estimated glomerular filtration rate; NAFLD, non-alcoholic fatty liver disease; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; HR, hazard ratio; CI, confidence interval. transformed for these analyses. P-values <0.05 were considered significant. Statistical analyses were performed with SPSS 25.0 for Windows (IBM, Armonk, New York, USA). The present study has been approved by the Ethics Committee of the University of Innsbruck, Austria, and written informed consent was given by all participants.
